Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
Thierra Guillaudeux, PhD, Chief Scientific Officer, Kineta Inc American Association of Cancer Research Annual Meeting | April 8, 2024
VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Thierry Guillaudeux; Shaarwari Sridhar; Emily Frazier; Yulia Ovechkina; Shawn Iadonato AACR Journal: Blood Cancer Discovery | March 4, 2024
A highly potent anti-VISTA antibody KVA12123 – a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
Shawn Iadonato, Yulia Ovechkina, Kurt Lustig, Jessica Cross, Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz, Remington Lance, David Peckham, Shaarwari Sridhar, Carla Talbaux, Isabelle Tihista, Mei X ...
VISTA a Potential New Immuno-Oncology Target in Acute Myeloid Leukemia
Thierry Guillaudeux, Shaarwari Sridhar, Emily Frazier, Yulia Ovechkina, Shawn Iadonato Blood - American Society of Hematology | November 28, 2023
VISTA-101: A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA alone and in combination with pembrolizumab in advanced solid tumors
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023
Clinical and Research Updates on the VISTA Immune Checkpoint: Immuno-oncology Themes and Highlights
Randolph J. Noelle, J. Louise Lines, Lionel D. Lewis, Robert E. Martell, Thierry Guillaudeux, Sam W. Lee, Kathleen M. Mahoney, Matthew D. Vesely, Jerome Boyd-Kirkup, Dhanya K. Nambiar and Andrew M. Sc ...
VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2023 | April 16, 2023
Next-generation immunotherapies to address cancer immune resistance
Thierry Guillaudeux, PhD, Chief Scientific Officer Antibody Engineering & Therapeutics Conference | December 7, 2022
KVA12123: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity
Thierry Guillaudeux, PhD, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2022 | November, 2022
KVA 12.1 a novel fully human anti-VISTA antibody to treat cancer patients with advanced solid tumors
Shaarwari Sridhar, Scientist at Kineta Tumor Myeloid-Directed Therapies Summit 2022 | June 14, 2022